Loading...
OTCM
FEED
Market cap205kUSD
Oct 30, Last price  
0.22USD
1D
0.95%
1Q
-94.14%
IPO
-100.00%
Name

Nanovibronix Inc

Chart & performance

D1W1MN
OTCM:FEED chart
P/E
—
P/S
0.08
EPS
—
Vol. 1Y
244.32%
Shs. 5Y
72.53%
Rev. 5Y
32.59%
Div Yld LY
—
Div Yld TTM
—
Revenues
3m
-0.20%
94,000166,000211,000203,000147,000229,000239,000318,000530,000623,0001,695,000752,0002,283,0002,558,0002,553,000
Net income
-18m
L+390.82%
-723,000-1,275,000-1,989,000-2,647,000-2,884,000-2,831,000-5,806,000-4,154,000-5,794,000-4,325,000-14,282,000-5,448,000-3,711,000-3,705,000-18,185,000
CFO
-9m
L+272.50%
-547,000-787,000-602,000-900,000-1,480,000-1,533,000-2,182,000-3,550,000-3,874,000-3,391,000-4,367,000-7,035,000-3,602,000-2,516,000-9,372,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NanoVibronix, Inc. focuses on developing non-surgical medical devices that stimulate biological responses. Its core offerings include UroShield and PainShield. The company's business activities span across several global markets, such as the United States, Europe, Australia, India, and Israel, in addition to other territories. This enterprise was founded by Harold Jacob and Jona Zumeris in September 2003, and its main corporate office is situated in Tyler, Texas.

Key people

Doron Besser
Chief Executive Officer, Director · since 2025
Nicole Fernandez-McGovern
Interim Chief Financial Officer · since 2025
Harold Jacob
Chief Medical Officer · since 2025
Martin Goldstein
Independent Director · since 2015
Thomas Mika
Independent Director · since 2015
Zeev Rotstein
Independent Director · since 2025
URL
https://envuemed.com
IPO date
Apr 24, 2015
Employees
9
Domiciled in
US
Incorporated in
US
Legal address
C/O PHS Corporate Services, Inc.
1313 N Market Street
Suite 5100
New Castle, DE 19801
US
Headquarters
105 Maxess Road
Suite S124
Melvville, NY 11747
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT